课题基金 / 基金详情

Leadership for HIV/AIDS Clinical Trials Networks; HIV Vaccine Trials Network

Leadership for HIV/AIDS Clinical Trials Networks; HIV Vaccine Trials Network
艾滋病毒/艾滋病临床试验网络的领导;
批准号:
8645800
负责人:
Peter B. Gilbert
金额:
$599.55万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-06-29 至 2013-12-31
关键词:
AIDS preventionAIDS/HIV problemAcquired Immunodeficiency SyndromeAdjuvantAdolescentAdultAgeAntibodiesAntigensBiological AssayCase Report FormCharacteristicsClinicalClinical TrialsClinical Trials DesignClinical Trials NetworkCollectionCombined VaccinesCommon Data ElementCommunitiesCommunity Health EducationConduct Clinical TrialsCoordination and CollaborationDataData CollectionData SetDevelopmentDisease ProgressionDoseEffectivenessEnrollmentEpidemicEvaluationFundingGeneticGenital systemGeographic LocationsGoalsGrantGuidelinesHIVHIV InfectionsHIV Vaccine Trials NetworkHIV riskHIV vaccineHIV-1Home environmentHumanImmune responseImmunityImmunology procedureIndividualInfectionInternationalLaboratoriesLaboratory StudyLeadershipLicensureLymphoid TissueMeasurementMediatingMethodologyMissionMonitorMucosal Immune ResponsesMucosal ImmunityNatural ImmunityPeripheral Blood Mononuclear CellPersonsPhasePhase II Clinical TrialsPlayPopulationPoxviridaePreventionPrevention ResearchPreventiveProcessProtocols documentationPublicationsQualifyingRandomizedRegimenReportingResearchRetrievalRiskRisk BehaviorsRoleRouteSafetyScheduleSecuritySeriesSiteSocial CharacteristicsStructureSurfaceSystemT-LymphocyteTestingTrainingUnited States National Institutes of HealthVaccinationVaccine ResearchVaccinesViralViremiaWomanantiretroviral therapycostcost effectivenessdata managementdefective adenoviral vectordesignefficacy evaluationefficacy trialexperiencefallshead-to-head comparisonhigh riskimmunogenicimmunogenicityimprovedmennoveloperationplasmid DNAprogramspublic health prioritiesresponsestandardize guidelinesstatistical centertransmission processvaccine candidatevaccine effectivenessvaccine efficacyvector

项目摘要

项目成果

Peter B. Gilbert的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This application to continue as the Statistical and Data Management Center (SDMC) for the HIV Vaccine Trials Network (HVTN) is one of three applications comprising the Leadership Group of the HVTN. The HVTN scientific agenda focuses exclusively on RFA priority number 1: 'Vaccine Researchand Development." This application describes howthe Statistical Center for HIV/AIDS Research& Prevention (SCHARP) will achieve the aims of the RFAto (1) provide statistical leadership for the design, conduct, analysis and publication of Network clinical trials/studies; (2) provide central data management capability that includes randomization, data set and case report form design, central storage, security, processing and retrieval of study results; (3) provide data management and protocol training throughout the Network; (4) provide data-focused clinical trials implementation, and operation; and (5) contribute to cross-Network efforts in developing common data elements and data interfaces. SCHARP has extensive experience in the design, conduct and analysis of global HIV vaccine and prevention studies. Thus, the systems we propose to use for data collection, managment, monitoring, and analysis are all well tested and in accordance with ICH guidelines. SCHARP statisticians will also develop and deploy novel statistical methodologies to increase the efficiency and rigor of the proposed program of HlV vaccine trials. The HIV/AIDS epidemic continues to expand in almost all regions of the world, with approximately 4.8 million new infections in 2003 (UNAIDS 2004 Report on the Global AIDS Epidemic). Finding a safe, effective vaccine that will protect persons against infection and/or disease progression is an international public- health priority. Only through clinical trials held to the highest scientific and regulatory standards willthis goal be achieved.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CoVPN Cross-Protocol Analyses
CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals